A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD
Circulation. Cardiovascular quality and outcomes · 474 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- McGill University
- Universidad u hospital
- McGill University Health Centre
Según 2 financiadores declarados.
Publicación
- Publicado
- 2011-04-12 · Circ Cardiovasc Qual Outcomes · vol. 4 · número 3 · págs. 337–345
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 656 citas · más que el 99% de estudios similares · 8.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Cholesterol and Lipid Metabolism
- Palabras clave
- apolipoprotein B, non-HDL cholesterol, LDL cholesterol, cardiovascular risk prediction, ischemic cardiovascular events, relative risk, HDL cholesterol, cardiovascular disease prevention
- MeSH
- humans, cardiovascular diseases, apolipoproteins b, risk factors, reproducibility of results, predictive value of tests, cholesterol, ldl, cholesterol, hdl, biomarkers
7 autores
- Allan D. Sniderman🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- Ken Williams🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- John H. Contois🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- Howard M. Monroe🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- Matthew McQueen🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- Jacqueline d Graaf🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
- Curt Daniel Furberg🇺🇸🇳🇱🇨🇦Our Lady of the Lake University; Radboud University Nijmegen; The University of Texas at San Antonio Health Science Center; University of Maine School of Law; McGill University Health Centre; Population Health Research Institute; Radboud University Medical Center; Royal Victoria Hospital; Johnson & Johnson (Canada); Wake Forest University Health Sciences; Wake Forest University; McMaster University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Whether apolipoprotein B (apoB) or non-high-density lipoprotein cholesterol (HDL-C) adds to the predictive power of low-density lipoprotein cholesterol (LDL-C) for cardiovascular risk remains controversial.
Methods and results
This meta-analysis is based on all the published epidemiological studies that contained estimates of the relative risks of non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular events. Twelve independent reports, including 233 455 subjects and 22 950 events, were analyzed. All published risk estimates were converted to standardized relative risk ratios (RRRs) and analyzed by quantitative meta-analysis using a random-effects model. Whether analyzed individually or in head-to-head comparisons, apoB was the most potent marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was intermediate (RRR, 1.34; 95% CI, 1.24 to 1.44). The overall comparisons of the within-study differences showed that apoB RRR was 5.7%>non-HDL-C (PLDL-C (PLDL-C (P=0.017). Only HDL-C accounted for any substantial portion of the variance of the results among the studies. We calculated the number of clinical events prevented by a high-risk treatment regimen of all those >70th percentile of the US adult population using each of the 3 markers. Over a 10-year period, a non-HDL-C strategy would prevent 300 000 more events than an LDL-C strategy, whereas an apoB strategy would prevent 500 000 more events than a non-HDL-C strategy.
Conclusions
These results further validate the value of apoB in clinical care.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.